SCHEMBL20239237

SCHEMBL20239237

Nc1nc(Cl)cc(Oc2ccc(CCNC(=O)O)cc2)n1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.65
RAB9A P51151 2/20 0.65
SMN1; SMN2 Q16637 3/20 0.61
KMT2A Q03164 4/20 0.57
MEN1 O00255 2/20 0.57
NPC1 O15118 1/20 0.46
PLAAT3 P53816 3/20 0.45
PLAAT5 Q96KN8 3/20 0.45
PLAAT2 Q9NWW9 3/20 0.45
PLAAT4 Q9UL19 3/20 0.45
EPHX2 P34913 3/20 0.44
LTA4H P09960 2/20 0.44
TAAR1 Q96RJ0 2/20 0.44
OPRM1 P35372 2/20 0.42
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239168 0.86 RAB9A (0.47) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL20259077 0.85 ALDH1A1 (0.62) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL20239189 0.85 RAB9A (0.46) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL20239165 0.81 DGAT2 (0.47) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL20239326 0.81 ALDH1A1 (0.43) ALDH1A1RAB9ASMN1; SMN2KMT2APLAAT3
SCHEMBL5338527 0.78 OPRM1 (0.54) PLAAT3PLAAT5PLAAT2PLAAT4EPHX2
SCHEMBL20239173 0.77 SMN1; SMN2 (0.46) ALDH1A1RAB9ASMN1; SMN2NPC1PLAAT3
SCHEMBL20239158 0.76 EPHX2 (0.43) ALDH1A1RAB9ASMN1; SMN2KMT2APLAAT3
SCHEMBL2773493 0.76 EPHX2 (0.70) ALDH1A1RAB9ASMN1; SMN2NPC1PLAAT3
SCHEMBL21332641 0.75 EPHX2 (0.58) ALDH1A1SMN1; SMN2PLAAT3PLAAT5PLAAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT ALDH1A1 1430/4885RAB9A 1170/4885SMN1; SMN2 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.